Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Daiichi Sankyo
Teva
Fish and Richardson
Chinese Patent Office
Chubb
Cerilliant
Queensland Health
Johnson and Johnson

Generated: May 27, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021658

« Back to Dashboard

NDA 021658 describes ALVESCO, which is a drug marketed by Astrazeneca Pharms and is included in one NDA. It is available from three suppliers. There are three patents protecting this drug. Additional details are available on the ALVESCO profile page.

The generic ingredient in ALVESCO is ciclesonide. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ciclesonide profile page.
Summary for 021658
Tradename:ALVESCO
Applicant:Astrazeneca Pharms
Ingredient:ciclesonide
Patents:3
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 021658
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658 NDA Physicians Total Care, Inc. 54868-5989 E 54868-5989-0
ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658 NDA Physicians Total Care, Inc. 54868-5990 E 54868-5990-0

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:AEROSOL, METERED;INHALATIONStrength0.08MG/INH
Approval Date:Jan 10, 2008TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:May 13, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:May 13, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Feb 1, 2028Product Flag?Substance Flag?Delist Request?
Patented Use:MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD

Expired US Patents for NDA 021658

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Pharms ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658-003 Jan 10, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658-002 Jan 10, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658-002 Jan 10, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Astrazeneca Pharms ALVESCO ciclesonide AEROSOL, METERED;INHALATION 021658-003 Jan 10, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Farmers Insurance
Boehringer Ingelheim
Julphar
Cantor Fitzgerald
McKesson
Queensland Health
Mallinckrodt
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.